Arecoline transdermal - Cogent Pharmaceuticals
Latest Information Update: 17 Oct 2002
At a glance
- Originator Cogent Pharmaceuticals
- Mechanism of Action Muscarinic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 29 Jun 2000 New profile
- 29 Jun 2000 Phase-I clinical trials for Alzheimer's disease in USA (Transdermal)